Paul Matteis
Stock Analyst at Stifel
(3.27)
# 1,172
Out of 4,479 analysts
78
Total ratings
47.46%
Success rate
2.1%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $25.68 | +36.32% | 1 | Jul 2, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $50 → $53 | $45.41 | +16.71% | 4 | Jun 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $215 → $295 | $248.41 | +18.76% | 7 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $26 → $21 | $15.81 | +32.83% | 4 | May 9, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $29 | $21.06 | +37.70% | 1 | Apr 30, 2024 | |
| ANRO Alto Neuroscience | Reiterates: Buy | $32 | $11.31 | +182.94% | 2 | Mar 25, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $35 → $41 | $34.50 | +18.84% | 2 | Mar 6, 2024 | |
| NGNE Neurogene | Initiates: Buy | $31 | $39.51 | -21.54% | 1 | Jan 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Buy | $101 | $82.16 | +22.94% | 5 | Dec 21, 2023 | |
| SAGE Sage Therapeutics | Maintains: Hold | $22 → $20 | $10.69 | +87.09% | 4 | Dec 18, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $141 → $144 | $138.11 | +4.26% | 5 | Dec 18, 2023 | |
| BIIB Biogen | Maintains: Buy | $315 → $287 | $225.72 | +27.15% | 6 | Dec 14, 2023 | |
| ALEC Alector | Upgrades: Buy | $8 → $15 | $4.27 | +251.29% | 3 | Dec 14, 2023 | |
| LXEO Lexeo Therapeutics | Initiates: Buy | $20 | $14.49 | +38.03% | 1 | Nov 28, 2023 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | $373 | $473.35 | -21.20% | 12 | Nov 22, 2023 | |
| VTGN VistaGen Therapeutics | Initiates: Buy | $12 | $3.43 | +250.36% | 1 | Nov 14, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $26 | $9.62 | +170.27% | 1 | Oct 10, 2023 | |
| PEPG PepGen | Reiterates: Buy | $24 | $16.62 | +44.40% | 2 | Jun 14, 2023 | |
| ALKS Alkermes | Maintains: Hold | $31 → $33 | $24.18 | +36.50% | 4 | Jun 6, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Buy | $50 → $54 | $41.17 | +31.16% | 2 | Aug 9, 2022 | |
| ATHA Athira Pharma | Downgrades: Hold | $36 → $5 | $2.49 | +100.80% | 2 | Jun 23, 2022 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $54 → $32 | $11.65 | +174.68% | 1 | Jun 8, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $24 | $3.95 | +507.59% | 1 | Feb 1, 2022 | |
| ELYM Eliem Therapeutics | Initiates: Buy | n/a | $6.62 | - | 1 | Sep 7, 2021 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | n/a | $2.27 | - | 1 | Jul 26, 2021 | |
| GHRS GH Research | Initiates: Buy | n/a | $11.81 | - | 1 | Jul 20, 2021 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | n/a | $13.90 | - | 1 | Mar 12, 2020 | |
| WVE Wave Life Sciences | Maintains: Outperform | n/a | $5.23 | - | 1 | Feb 21, 2018 | |
| CDTX Cidara Therapeutics | Initiates: Outperform | $340 | $11.92 | +2,753.55% | 1 | Dec 21, 2016 |
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $25.68
Upside: +36.32%
Ionis Pharmaceuticals
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $45.41
Upside: +16.71%
Alnylam Pharmaceuticals
Jun 27, 2024
Maintains: Buy
Price Target: $215 → $295
Current: $248.41
Upside: +18.76%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $15.81
Upside: +32.83%
Contineum Therapeutics
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $21.06
Upside: +37.70%
Alto Neuroscience
Mar 25, 2024
Reiterates: Buy
Price Target: $32
Current: $11.31
Upside: +182.94%
Dyne Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $35 → $41
Current: $34.50
Upside: +18.84%
Neurogene
Jan 5, 2024
Initiates: Buy
Price Target: $31
Current: $39.51
Upside: -21.54%
BioMarin Pharmaceutical
Dec 21, 2023
Reiterates: Buy
Price Target: $101
Current: $82.16
Upside: +22.94%
Sage Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $22 → $20
Current: $10.69
Upside: +87.09%
Neurocrine Biosciences
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $138.11
Upside: +4.26%
Biogen
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $225.72
Upside: +27.15%
Alector
Dec 14, 2023
Upgrades: Buy
Price Target: $8 → $15
Current: $4.27
Upside: +251.29%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $14.49
Upside: +38.03%
Vertex Pharmaceuticals
Nov 22, 2023
Reiterates: Hold
Price Target: $373
Current: $473.35
Upside: -21.20%
VistaGen Therapeutics
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $3.43
Upside: +250.36%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $9.62
Upside: +170.27%
PepGen
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $16.62
Upside: +44.40%
Alkermes
Jun 6, 2023
Maintains: Hold
Price Target: $31 → $33
Current: $24.18
Upside: +36.50%
Cerevel Therapeutics Holdings
Aug 9, 2022
Maintains: Buy
Price Target: $50 → $54
Current: $41.17
Upside: +31.16%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $2.49
Upside: +100.80%
KalVista Pharmaceuticals
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.65
Upside: +174.68%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $3.95
Upside: +507.59%
Eliem Therapeutics
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $6.62
Upside: -
Acumen Pharmaceuticals
Jul 26, 2021
Initiates: Buy
Price Target: n/a
Current: $2.27
Upside: -
GH Research
Jul 20, 2021
Initiates: Buy
Price Target: n/a
Current: $11.81
Upside: -
Avadel Pharmaceuticals
Mar 12, 2020
Initiates: Buy
Price Target: n/a
Current: $13.90
Upside: -
Wave Life Sciences
Feb 21, 2018
Maintains: Outperform
Price Target: n/a
Current: $5.23
Upside: -
Cidara Therapeutics
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $11.92
Upside: +2,753.55%